SpaceX and OpenAI tokenized shares and AI-designed drugs

Episode SummaryIn episode 20, Nish records from a tropical war zone of broken podcast gear while Michiel holds steady with TradFi tech picks and an 8 percent portfolio gain. The episode opens with Robinhood’s wild move to offer tokenized shares of OpenAI and SpaceX, raising questions after OpenAI denied any involvement. The hosts break down how this ties into the broader risk landscape post-SVB, with stablecoins like Tether still lacking a real audit, and USDC emerging as the safer bet. They also explore why OpenAI still can’t go public, how Microsoft quietly benefits through a revenue-sharing deal, and how Nvidia is nearing a 4 trillion dollar valuation despite a China sales ban. One of the biggest tech stories: DeepMind has launched the first human trial of a drug designed entirely by AI, potentially compressing the pharmaceutical pipeline by years. Meanwhile,Samsung predicts a 40 percent drop in quarterly profits due to weak AI chip sales, showing the gap between AI hype and hardware reality. In fintech, Soulflare adds stock trading with zero KYC or announcement, raising regulatory questions. And in thetrading competition, Nish gets rugged again on Pump.Fun and drops to 24 dollars, while Michiel’s conservative picks push him to an 8 percent gain. The episode closes with reflections on market delusion, geopolitical risks, and a plea to the Illuminati to stop messing with their portfolios.Links1. Robinhood launches tokens for EU users:https://www.reuters.com/business/robinhood-launches-tokens-allowing-eu-users-trade-us-stocks-2025-06-30/2. OpenAI says it has not partnered with Robinhood:https://www.reuters.com/business/openai-says-it-has-not-partnered-with-robinhood-stock-token-2025-07-02/3. SEC chair comments on tokenized equities:https://www.marketwatch.com/story/these-stocks-surged-as-sec-chair-sounds-positive-on-tokenization-of-equities-1a1528a14. Google DeepMind AI-Designed Drug Trials: https://www.fastcompany.com/91363911/googles-ai-drug-company-says-human- trials-are-very-closeStablecoins & SVB Fallout5. Stablecoins and bank profit risks:https://www.marketwatch.com/story/stablecoins-could-hurt-bank-profits-but-not-for-a-while-analyst-673b57786. Academic research on USDC vs USDT during SVB collapse:https://arxiv.org/abs/2407.11716 Chapter List1. 00:00 — Tropic Thunder in Thailand and Podcast Tech Fail2. 01:30 — Robinhood Offers Tokenized OpenAI and SpaceX Shares3. 03:00 — DeFi Meets TradFi: Stablecoins and the SVB Risk Model4. 05:00 — Tether’s First Audit and Why It Still Isn’t Trustworthy5. 07:00 — Why OpenAI Still Can’t Go Public and Who Owns It6. 09:30 — Microsoft Quietly Wins with OpenAI’s Future Revenue7. 10:30 — Nvidia Hits $4 Trillion Despite China Sales Ban8. 11:00 — China and Australia Discuss AI Trade Collaboration9. 11:30 — DeepMind Launches First Human Trial of AI-Designed Drug10. 13:00 — Samsung Forecasts 40 Percent Profit Drop on Weak AI Chip Sales11. 14:30 — Soulflare Adds Stock Trading with Zero KYC or Announcement12. 15:30 — World War III Already Happening? Markets Don’t Care13. 17:00 — Stocks Beat Bitcoin in June Despite Global Tension14. 18:00 — Fear and Greed Index Swings and Market Confusion15. 19:30 — Trading Competition: Nish Gets Rugged Again on Pump.Fun16. 22:00 — Michiel’s Portfolio: Up 8 Percent with Nvidia and Broadcom17. 24:30 — Risk Lessons and the Problem with Holding Too Long18. 26:00 — Final Thoughts: Peace, Perspective, and Market Madness TagsRobinhood, Tokenized stocks, OpenAI, SpaceX, USDT, USDC, Tether audit, Stablecoins, DeepMind, AI drug trial, Microsoft, OpenAI IPO, Nvidia, Soulflare, No KYC, Pump.Fun, Rug pull, Bitcoin, Fear and Greed Index, Trading competition, NFA Podcast, Nisheta Sachdev, Michiel Frackers